Barclays analyst Michael Leithead upgraded Olin to Overweight from Equal Weight with a price target of $65, up from $60. Chlor-alkali supply/demand remains relatively tight, and the company’s shareholder remunerations "remain healthy and clearly-defined," Leithead tells investors in a research note. The analyst thinks Olin’s valuation underappreciates its "much-improved" free cash flow conversion and capital discipline.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly